Literature DB >> 25677259

Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality.

M Slavin1, S van Hal2, T C Sorrell3, A Lee4, D J Marriott5, K Daveson6, K Kennedy6, K Hajkowicz7, C Halliday8, E Athan9, N Bak10, E Cheong11, C H Heath12, C Orla Morrissey13, S Kidd14, R Beresford5, C Blyth15, T M Korman16, J Owen Robinson17, W Meyer18, S C-A Chen19.   

Abstract

The epidemiology of invasive fungal disease (IFD) due to filamentous fungi other than Aspergillus may be changing. We analysed clinical, microbiological and outcome data in Australian patients to determine the predisposing factors and identify determinants of mortality. Proven and probable non-Aspergillus mould infections (defined according to modified European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria) from 2004 to 2012 were evaluated in a multicentre study. Variables associated with infection and mortality were determined. Of 162 episodes of non-Aspergillus IFD, 145 (89.5%) were proven infections and 17 (10.5%) were probable infections. The pathogens included 29 fungal species/species complexes; mucormycetes (45.7%) and Scedosporium species (33.3%) were most common. The commonest comorbidities were haematological malignancies (HMs) (46.3%) diabetes mellitus (23.5%), and chronic pulmonary disease (16%); antecedent trauma was present in 21% of cases. Twenty-five (15.4%) patients had no immunocompromised status or comorbidity, and were more likely to have acquired infection following major trauma (p <0.01); 61 (37.7%) of cases affected patients without HMs or transplantation. Antifungal therapy was administered to 93.2% of patients (median 68 days, interquartile range 19-275), and adjunctive surgery was performed in 58.6%. The all-cause 90-day mortality was 44.4%; HMs and intensive-care admission were the strongest predictors of death (both p <0.001). Survival varied by fungal group, with the risk of death being significantly lower in patients with dematiaceous mould infections than in patients with other non-Aspergillus mould infections. Non-Aspergillus IFD affected diverse patient groups, including non-immunocompromised hosts and those outside traditional risk groups; therefore, definitions of IFD in these patients are required. Given the high mortality, increased recognition of infections and accurate identification of the causative agent are required.
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Determinants of outcome; epidemiology; filamentous fungus; non-Aspergillus moulds; predisposing factors

Mesh:

Substances:

Year:  2015        PMID: 25677259     DOI: 10.1016/j.cmi.2014.12.021

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  36 in total

1.  Performance of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Aspergillus, Scedosporium, and Fusarium spp. in the Australian Clinical Setting.

Authors:  Sue Sleiman; Catriona L Halliday; Belinda Chapman; Mitchell Brown; Joanne Nitschke; Anna F Lau; Sharon C-A Chen
Journal:  J Clin Microbiol       Date:  2016-06-01       Impact factor: 5.948

2.  Discrimination of Aspergillosis, Mucormycosis, Fusariosis, and Scedosporiosis in Formalin-Fixed Paraffin-Embedded Tissue Specimens by Use of Multiple Real-Time Quantitative PCR Assays.

Authors:  Elham Salehi; Mohammad T Hedayati; Jan Zoll; Haleh Rafati; Maryam Ghasemi; Atosa Doroudinia; Mahdi Abastabar; Ali Tolooe; Eveline Snelders; Henrich A van der Lee; Antonius J M M Rijs; Paul E Verweij; Seyedmojtaba Seyedmousavi; Willem J G Melchers
Journal:  J Clin Microbiol       Date:  2016-09-07       Impact factor: 5.948

3.  Clinical Spectrum, Diagnosis and Outcome of Rare Fungal Infections in Patients with Hematological Malignancies: Experience of 15-Year Period from a Single Tertiary Medical Center.

Authors:  Emilia Hardak; Eyal Fuchs; Yuval Geffen; Tsila Zuckerman; Ilana Oren
Journal:  Mycopathologia       Date:  2020-02-25       Impact factor: 2.574

Review 4.  Proteomics as a Tool to Identify New Targets Against Aspergillus and Scedosporium in the Context of Cystic Fibrosis.

Authors:  Andoni Ramirez-Garcia; Aize Pellon; Idoia Buldain; Aitziber Antoran; Aitana Arbizu-Delgado; Xabier Guruceaga; Aitor Rementeria; Fernando L Hernando
Journal:  Mycopathologia       Date:  2017-05-08       Impact factor: 2.574

5.  Rare cause of pulmonary cavitation in a 75-year-old man.

Authors:  Jaffar Al-Sheikhli; Hussein Taqi; John Drake; Ayaaz Habib
Journal:  BMJ Case Rep       Date:  2018-01-10

6.  Evaluation of ID Fungi Plates Medium for Identification of Molds by MALDI Biotyper.

Authors:  Marie Gladys Robert; Charlotte Romero; Céline Dard; Cécile Garnaud; Odile Cognet; Thomas Girard; Tahinamandranto Rasamoelina; Muriel Cornet; Danièle Maubon
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

7.  Invasive Fungal Disease in Patients with Chronic Lymphocytic Leukemia in Japan: A Retrospective Database Study.

Authors:  Takeo Yasu; Kotono Sakurai; Manabu Akazawa
Journal:  Curr Oncol       Date:  2022-05-04       Impact factor: 3.109

8.  Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections.

Authors:  Frédéric Lamoth; Lauro Damonti; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2016-03-23       Impact factor: 5.948

9.  Sensitivity of liquid-based cytology in the diagnosis of mucormycosis in COVID-19 treated patients.

Authors:  Rabish Kumar; Meeta Singh; Tanu Sagar; M Bharanidharan; Nita Khurana; Vikas Kumar; Ravi Meher; Vikas Malhotra; Ruchi Goel; Sonal Saxena; Jyoti Kumar
Journal:  Cytopathology       Date:  2022-04-18       Impact factor: 1.286

10.  In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis.

Authors:  S Seyedmousavi; Y C Chang; J H Youn; D Law; M Birch; J H Rex; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.